NYXH PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

NYXH ▲ +4.87% at T+20d

LONG call ✓ call won +4.87% · α vs SPY -4.45% · entry $3.08 → $3.23

Next anchor: T+60d in 5d

Last close $1.39 (close Jun 8) · -54.87% from $3.08 entry

Entry anchored
Mar 19, 03:42 PM ET
via Databento tick

T+1d

+2.60%

call +2.60% · α +1.49%

$3.16

settled 3mo ago

T+5d

-8.44%

call -8.44% · α -6.29%

$2.82

settled 3mo ago

T+20d

+4.87%

call +4.87% · α -4.45%

$3.23

settled 8w ago

T+60d

—

call — · α —

—

in 5d

Price Chart

Loading chart...

Executive Summary

Nyxoah reported strong fourth-quarter and full-year 2025 financial results, driven by the first full quarter of U.S. commercialization of its Genio system for sleep apnea. Q4 net revenue reached €5.6 million, up 347% year-over-year, with 64% gross margin. The company guided for 25% sequential net revenue growth in each of the next two quarters, signaling strong momentum in its U.S. launch.

Key Financial Metrics

Revenue

$5.6M

+347.0% YoY

EPS

$-2.36

Actionable Insight

The 25% sequential revenue growth guidance suggests accelerating commercial traction; traders should monitor Q1 2026 revenue and account expansion metrics. Strong reimbursement support from Medicare and commercial payors reduces adoption risk.

Key Facts

Q4 2025 net revenue: €5.6 million (347% YoY growth) vs. €1.3 million in Q4 2024
Full-year 2025 net revenue: €10.0 million (122% YoY growth) vs. €4.5 million in 2024
Q4 gross margin: 64%, despite operational ramp-up costs
145 surgeons trained and 57 U.S. accounts activated as of December 31, 2025
Guidance: ~25% sequential net revenue growth expected in Q1 and Q2 2026
Cash, cash equivalents, and financial assets: €48.0 million as of December 31, 2025

Financial Impact

Net revenue grew from €1.3M to €5.6M in Q4 YoY (347% growth), with path to ~€8.75M in Q2 2026 based on guidance

revenuegross_margincash_position

Risk Factors

Operating losses widened to €83.5M in 2025 from €58.8M in 2024 due to commercial investments
Gross margin declined slightly YoY (66% to 63%) due to launch-related inefficiencies
High R&D and SG&A spending may pressure cash runway despite current €48M balance

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3259442

8 reports for NYXH

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for NYXH — sortable, filterable
	Type				Now
Jun 8, 2026 1d ago	6-K BEARISH ★ 7/10	$1.36 awaiting T+5	awaiting T+5	—	$1.39 (−2.21%)
Jun 8, 2026 1d ago	424B5 BEARISH ★ 7/10	$1.69 awaiting T+5	awaiting T+5	—	$1.39 (+17.75%)
Jun 5, 2026 4d ago	Press Release BEARISH ★ 7/10	$1.59 awaiting T+5	awaiting T+5	—	$1.39 (+12.58%)
Jun 4, 2026 5d ago	424B5 BEARISH ★ 7/10	$1.73 awaiting T+5	awaiting T+5	—	$1.39 (+19.65%)
May 20, 2026 20d ago	Press Release BULLISH ★ 5/10	$2.87 $2.99	▲ +4.18%	▲ +2.58%	$1.39 (−51.57%)
May 12, 2026 28d ago	Press Release MIXED ★ 6/10	$3.08 $2.81	▼ −8.77%	▼ −7.61%	$1.39 (−54.87%)
Mar 19, 2026 11w ago	Press Release BULLISH ★ 8/10	$3.08 $2.82	▼ −8.44%	▼ −6.29%	$1.39 (−54.87%)
Mar 5, 2026 13w ago	Press Release NEUTRAL ★ 3/10	$3.74 $3.14	▼ −16.04%	▼ −14.51%	$1.39 (−62.83%)

US Market Status

Market Closed — Opens in 8h 32m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access